drugset / Trial / NCT00734292

Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma

NCT00734292

Phase 2 Completed 39 enrolled SkyePharma AG Abbott · collab
RandomizedCrossoverDouble-blind

Summary

The primary purpose of this study is to evaluate the early bronchodilating effect of SKP FlutiForm HFA pMDI compared to placebo.

Timeline

Start
2008-09
Primary completion
2008-09
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fluticasone propionate Other / unclassified 100 ug Inhaled
Comparator Fluticasone propionate Other / unclassified 250 ug Inhaled
Comparator Formoterol Other / unclassified 10 ug Inhaled

Indications